• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Can-Fite Biopharma Ltd ADR (NY: CANF )

    2.190 +0.040 (+1.86%)
    Official Closing Price Updated: 6:30 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Can-Fite Biopharma Ltd ADR

    < Previous 1 2 3 4 5 6 7 Next >
    Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug
    Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
    Via Benzinga
    Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022
    Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week... 
    Via Benzinga
    Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates
    Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:C... 
    Via Benzinga
    Earnings Scheduled For November 26, 2021
    Companies Reporting Before The Bell Pinduoduo Inc. (NASDAQ:PDD) is expected to report quarterly earnings at $0.02 per share on revenue of $4.16 billion. BlueCity Holdings Limited... 
    Via Benzinga
    Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite's Kickstarts Piclidenoson Study For Canine Osteoarthritis
    Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs. Safety results are expected in... 
    Via Benzinga
    Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
    PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule... 
    Via Benzinga
    Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial
    Photo by National Cancer Institute on Unsplash Liver cancer is a growing global health concern. Apart from the financial burden it places on patients and economies, the American... 
    Via Benzinga
    Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    The Week In Cannabis: $1.25B+ In Financings And M&A, Tilray, KushCo, New York And More
    Below is a recap of the main news related to the cannabis industry and markets for the week of August 27, 2021. 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY
    Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021. The Israel-based company... 
    Via Benzinga
    Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Announces $10.0 Million Registered Direct Offering
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
    Via Benzinga
    Topics Product Recall
    Exposures COVID-19 Legal Product Safety
    Can-Fite Stock Gains On Piclidenoson Development Pact For Pets
    Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to... 
    Via Benzinga
    Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.